in Portfolio News
Quell Therapeutics, an SV portfolio company which recently entered into an exclusive option and license agreement with AZ receiving $85m upfront and a potential further $2bn for development and commercialisation milestones has been interviewed by The Times
We invest in talented innovators. We strongly adhere to the view that diversity, including under-represented groups, strongly adds to success. If you are an entrepreneur seeking investment and a partner who can help you to build your business, we would love to hear from you. Please get in contact with our team.